[1] Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O.,
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma,
N. Engl. J. Med., 352: 987-996 (2005).
[9] Britten C.D., Rowinsky E.K., Baker S.D., Agarwala S.S., Eckardt J.R., Barrington R., Diab S.G., Hammond L.A., Johnson T., Villalona-Calero M., Fraass U., Statkevich P., Von Hoff D.D., Eckhardt S.G.,
A Phase I and Pharmacokinetic Study of Temozolomide and Cisplatin in Patients with Advanced Solid Malignancies, Clin. Cancer Res.,
5: 1629–1637 (1999).
[13] Kim H.K., Lin C.C., Parker D., Veals J., Lim J., Likhari P., Statkevich P., Marco A.,
Nomeir A.A., High-Performance Liquid Chromatographic Determination and Stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the Biologically Active Product of the Antitumor Agent Temozolomide in Human Plasma,
J. Chromatogr. B,
703: 225-233 (1997).